Meeting
2023 ASCO Annual Meeting
Potential predictive biomarker for response to radiotherapy and CXCL12 inhibition in glioblastoma in the phase I/II GLORIA trial.
Authors
Frank Anton Giordano
Department of Radiation Oncology, University Medical Center Mannheim, University of Heidelberg, Mannheim, Germany
Frank Anton Giordano , Julian Philipp Layer , Sonia Leonardelli , Lea Lydia Friker , Roberta Turiello , Dillon Corvino , Thomas Zeyen , Christina Schaub , Wolf Mueller , Leonard Christopher Schmeel , Katharina Sahm , Sied Kebir , Peter Hambsch , Torsten Pietsch , Sotirios Bisdas , Martin Glas , Clemens Seidel , Ulrich Herrlinger , Michael Hölzel , Elena Sperk
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Central Nervous System Tumors
Track
Central Nervous System Tumors
Sub Track
Primary CNS Tumors–Glioma
Clinical Trial Registration Number
NCT04121455
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr 2048)
DOI
10.1200/JCO.2023.41.16_suppl.2048
Abstract #
2048
Poster Bd #
405
Abstract Disclosures
Similar Posters
Poster
2018 ASCO Annual Meeting
Phase 1b/2 study of pexidartinib (PEX) in combination with radiation therapy (XRT) and temozolomide (TMZ) in newly diagnosed glioblastoma.
First Author: Howard Colman
Poster
2022 ASCO Annual Meeting
Clinical application of a functional 3D ex vivo test to predict therapeutic response in patients with HGG: A progression-free survival analysis.
First Author: Lindsay J Lipinski
Poster
2022 ASCO Annual Meeting
Bortezomib sensitization of recurrent glioblastoma with unmethylated MGMT promoter to temozolomide, a phase II study (NCT03643549).
First Author: Dorota Goplen
Poster
2020 ASCO Virtual Scientific Program
Phase III TRIDENT trial: Radiation and temozolomide +/- tumor treating fields in newly diagnosed glioblastoma.
First Author: Wenyin Shi